🎥 Kuldeep Dubey's Inspiring Journey with NexCAR19™ #ImmunoACT #CAR_TCellTherapy #PatientJourneyTestimonial #HealthcareInnovation #CancerRemission Rahul Purwar Shirish Arya Atharva Karulkar Advanced Centre for Treatment, Research and Education in Cancer(ACTREC) ImmunoACT Carl June National Cancer Institute (NCI) Indian Institute of Technology, Bombay Government of India (GoI) ISCT, International Society for Cell & Gene Therapy Biotechnology Industry Research Assistance Council (BIRAC) Cell & Gene Therapy Insights Indian Council of Medical Research (ICMR) Tata Memorial Centre Department of Biotechnology Department of Science and Technology
ImmunoACT
Biotechnology Research
Navi Mumbai, Maharashtra 21,961 followers
India's Leader in Cell & Gene Therapies
About us
Spun-out from IIT-Bombay in 2018, ImmunoACT is India's pioneer in the development of the country's first indigenous Cell & Gene Therapy. With a rapidly expanding pipeline beginning with blood cancers, our mission is to provide affordable access to novel autologous CAR-T cell therapies.
- Website
-
http://ImmunoACT.com
External link for ImmunoACT
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Navi Mumbai, Maharashtra
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Cell & Gene Therapies, Translational Research, and Viral Vector Process Development & Manufacturing
Locations
-
Primary
Get directions
ImmunoACT, 1st Floor, R-977
T.T.C. Industrial Area, MIDC Rabale
Navi Mumbai, Maharashtra 400701, IN
Employees at ImmunoACT
-
U HARI KRISHNAN
Zonal Medical Advisor at ImmunoACT
-
Shreewardhan Rajopadhye, PhD
Upstream Process Development & Manufacturing Scientist | CGTs & Biologics | Discovery to Clinic to Commerical
-
Ashish Saroha, PhD
Research Scientist/Oncology/Cell and gene therapy/ CAR-T Cell manufacturing and R&D / immunotherapy/glycobiology/proteomics
-
Ankush Korishettar
Senior Scientist @ ImmunoACT | Antibody Discovery, CAR-T Cell Therapy
Updates
-
ImmunoACT Featured in the Times of India! 🎉 We’ve received a special feature mention in the Medical Breakthroughs of 2024 by the Times of India [January 1, 2025]! ImmunoACT continues to strive to broaden, expand, and improve access to NexCAR19 (Talicabtagene autoleucel), a potentially life-saving CAR T-cell therapy for the treatment of B-cell lymphomas & B-cell acute lymphoblastic leukaemia in settings where frontline or subsequent therapies have been inadequate to achieve a response. #MedicalBreakthroughs #TimesOfIndia #ImmunoACT #CAR_TCellTherapy #InnovationInHealthcare
-
-
We are excited to announce our collaboration with Bhagwan Mahaveer Cancer Hospital & Research Centre (BMCHRC), Jaipur! Under the visionary leadership of Major General Dr Subhash chandra Pareek (Executive Director) and Dr Prakash Singh Shekhawat, this collaboration marks the commencement of BMCHRC Jaipur's CAR-T program. This partnership will enable access to NexCAR19™ and our pipeline of CAR-T cell therapies at their state-of-the-art oncology treatment center. It represents a significant step in advancing treatment options for patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin’s Lymphoma (B-NHL) in Rajasthan and across India. Our commitment remains steadfast: to bridge the gaps in affordability and accessibility of life-saving CAR-T therapies, empowering patients with better survival outcomes and enhanced quality of life. #ImmunoACT #BMCHRC #CARTCellTherapy #NexCAR19 #CancerCareIndia
-
-
We’re #hiring ! To be a part of our journey, email your CV to jobs@immunoact.com. We’re excited to connect with you!
-
We’re #hiring ! To be a part of our journey, email your CV to jobs@immunoact.com. We’re excited to connect with you!
-
We’re #hiring ! To be a part of our journey, email your CV to jobs@immunoact.com. We’re excited to connect with you!
-
We’re #hiring ! To be a part of our journey, email your CV to jobs@immunoact.com. We’re excited to connect with you!
-
Fortis Healthcare emerged as a centre of excellence in early adoption of CAR-T cell therapies. On December 6, 2024, Dr. Akash Khandelwal, Consultant Hemato-Oncology & BMT, Fortis Shalimar Bagh & ImmunoACT held a joint outreach session amongst interpreters of the international medical community to outline the process of access & treatment with NexCAR19 (Talicabtagene autoleucel), India's first indigenous CAR-T cell therapy for certain B-cell cancers that have failed one or more lines of prior treatments. We at ImmunoACT strive to broaden access to our life-saving CAR-T cell therapies to patients across borders and socio-economic backgrounds #CAR_TCellTherapy #FortisHealthcare #ImmunoACT #NexCAR19 #HematoOncology #CancerCareInnovation #GlobalHealthCare #MadeInIndiaHealthcare #LifeSavingTherapies #HealthcareForAll
-